This study sought to report the incidence of device-related thrombosis (DRT) and thromboembolic (TE) events when an alternative to clopidogrel is prescribed in loss-of-function (LOF) allele carriers of the cytochrome P450 2C19 (CYP2C19) gene.
Incidence of device-related thrombosis in watchman patients undergoing a genotype-guided antithrombotic strategy / Della Rocca, D.G., Horton, R.P., Di Biase, L., Gianni, C., Trivedi, C., Mohanty, S., Anannab, A., Magnocavallo, M., Chen, Q., Tarantino, N., Bassiouny, M., Lavalle, C., Natale, V.N., Forleo, G.B., Del Prete, A., Van Niekerk, C.J., Al-Ahmad, A., Burkhardt, J.D., Gallinghouse, G.J., Sanchez, J.E., et al.. - In: JACC. CLINICAL ELECTROPHYSIOLOGY. - ISSN 2405-500X. - 7:12(2021), pp. 1533-1543. [10.1016/j.jacep.2021.04.012]
Incidence of device-related thrombosis in watchman patients undergoing a genotype-guided antithrombotic strategy
Magnocavallo, Michele;Lavalle, Carlo;
2021
Abstract
This study sought to report the incidence of device-related thrombosis (DRT) and thromboembolic (TE) events when an alternative to clopidogrel is prescribed in loss-of-function (LOF) allele carriers of the cytochrome P450 2C19 (CYP2C19) gene.| File | Dimensione | Formato | |
|---|---|---|---|
|
DellaRocca_Incindence_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.44 MB
Formato
Adobe PDF
|
1.44 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
